Comparison
Bremelanotide vs. Selank
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Research other
Research other
CAS no.
189691-06-3
129954-34-3
Molecular weight
1025.18 g/mol
751.85 g/mol
Half-life
2.7 h
0.3 h
Sequence
Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-OHThr-Lys-Pro-Arg-Pro-Gly-ProMechanism of action
Bremelanotide
Bremelanotide is a cyclic peptide that binds non-selectively to melanocortin receptors (MC1R through MC5R) — with highest affinity at MC4R in the central nervous system. The precise role of MC4R activation in sexual behaviour is not fully understood; animal data show effects on hypothalamic circuits. Peripheral effects (blood pressure, hyperpigmentation) are attributed to MC1R/MC2R.
Selank
Selank is a glyproline-tuftsin analog. Proposed mechanisms include modulation of the GABAergic system, effects on serotonin bioavailability, and influence on enkephalinases. Animal studies show anxiolytic and neuroprotective markers; a clear receptor target is not established.
Evidence base
Highest evidence
Human RCT
Human trial
Studies
5
4
of which in humans
5
2
Effects recorded
3
3
Open conflicts
1
1
Documented adverse events
2
1
Legal status
Full entries
Frequently asked questions
- What is the difference between Bremelanotide and Selank?
- Bremelanotide is classified as "Research other", while Selank is classified as "Research other". Bremelanotide: Synthetic cyclic heptapeptide acting as a non-selective melanocortin-receptor agonist. FDA-approved in 2019 as Vyleesi for hypoactive sexual desire disorder (HSDD) in pre-menopausal women. Selank: Synthetic heptapeptide derived from natural tuftsin. Approved as an anxiolytic (Selank) in Russia and some CIS states. Western phase-3 trials are absent; efficacy assessment relies on Russian research literature. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Bremelanotide or Selank?
- The highest available evidence level is "Human RCT" for Bremelanotide and "Human trial" for Selank. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Bremelanotide and Selank in Germany and the United States?
- Germany: Bremelanotide — Unapproved, Selank — Unapproved. United States: Bremelanotide — Prescription, Selank — Unapproved. These are factual summaries with source and review date on the individual pages.